RadNet Stock (NASDAQ:RDNT)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$53.08

52W Range

$45.00 - $93.65

50D Avg

$54.10

200D Avg

$64.60

Market Cap

$3.74B

Avg Vol (3M)

$940.87K

Beta

1.59

Div Yield

-

RDNT Company Profile


RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems for the diagnostic imaging industry, including picture archiving communications systems and related services; and develops and deploys AI suites to enhance radiologist interpretation of images in the field of mammography, as well as AI solutions for lung and prostate cancer. As of December 31, 2021, it owned and managed 347 centers in Arizona, California, Delaware, Florida, Maryland, New Jersey, and New York. The company was founded in 1981 and is headquartered in Los Angeles, California.

Show More

Industry

Medical - Diagnostics & Research

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

8,546

IPO Date

Jan 03, 1997

Website

RDNT Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 24Dec 23Dec 22
Workers' Compensation/Personal Injury1$43.67M$47.36M$51.34M
Medicaid1$44.74M$43.17M$38.28M
Commercial Insurance1$1.02B$897.95M$785.13M
Health Care, Management Service$24.68M$17.94M$22.23M
Capitation Arrangements$136.57M$153.43M$152.04M
Health Care, Other$46.72M$20.11M$19.43M
Medicare1$410.07M$363.86M$311.12M
Software and Teleradiology-$18.08M$14.24M
Health Care, Patient Service Other-$42.25M$31.85M

Fiscal year ends in Dec 24 | Currency in USD

RDNT Financial Summary


Dec 24Dec 23Dec 22
Revenue$1.83B$1.62B$1.43B
Operating Income$104.62M$98.70M$46.36M
Net Income$50.89M$3.04M$33.61M
EBITDA$262.55M$292.79M$278.53M
Basic EPS$0.70$0.05$0.60
Diluted EPS$0.68$0.05$0.59

Fiscal year ends in Dec 24 | Currency in USD

Latest Earnings Call Transcripts


Q4 24Feb 28, 25 | 10:30 AM
Q3 24Nov 11, 24 | 10:30 AM
Q2 24Aug 08, 24 | 10:30 AM

Peer Comparison


TickerCompany
XGNExagen Inc.
BNRBurning Rock Biotech Limited
ACRSAclaris Therapeutics, Inc.
NEOGNeogen Corporation
BDSXBiodesix, Inc.
QGENQiagen N.V.
MYGNMyriad Genetics, Inc.
SERASera Prognostics, Inc.
FONRFONAR Corporation
SHCSotera Health Company